MYC and acute myeloid leukemia: Indeed, overexpression of Myc has been reported to be associated with adverse clinical outcome and drug resistance in AML.37, 38 However, definitive conclusions about quinacrine being a selective pol-I inhibitor will require further more detailed molecular studies.